SCHEMBL327800

SCHEMBL327800

Cc1ccc(N2C[C@@H](C)O[C@@H](C)C2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
ALDH1A1 P00352 7/20 0.54
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
RAB9A P51151 1/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 1/20 0.44
ADRB1 P08588 1/20 0.44
GAK O14976 1/20 0.43
KMT2A Q03164 2/20 0.43
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23731989 1.00 MAPT (0.57) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL18436831 1.00 MAPT (0.57) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL7790503 1.00 MAPT (0.57) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL24352865 1.00 MAPT (0.57) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL18435963 0.84 MAPT (0.44) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL19012372 0.82 MAPT (0.46) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL19012683 0.82 MAPT (0.46) MAPTALDH1A1CYP2C19CYP1A2CYP3A4
SCHEMBL13370273 0.82 MAPT (0.56) MAPTALDH1A1LMNAGAAL3MBTL1
SCHEMBL2385628 0.82 MAPT (0.56) MAPTALDH1A1LMNAGAAL3MBTL1
SCHEMBL6133073 0.82 MAPT (0.56) MAPTALDH1A1LMNARAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS ENYO PHARMA (FR) 2023-10-12 US disclosed
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones Impact Therapeutics (Shanghai), Inc (CN) 2022-05-31 US disclosed
EP-3204382-B1 HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-12-01 EP disclosed
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2020-12-10 US disclosed
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones IMPACT THERAPEUTICS, INC (CN) 2020-07-07 US disclosed
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES Impact Therapeutics (Shanghai), Inc (CN) 2019-10-10 US disclosed
WO-2019154956-A1 NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
EP-3124482-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-02-01 EP disclosed
US-20090043094-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES SHIONOGI & CO., LTD. (JP) 2009-02-12 US disclosed
US-20090043094-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES SHIONOGI & CO., LTD. (JP) 2009-02-12 US disclosed
US-7459580-B2 Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives SHIONOGI & CO., LTD. (JP) 2008-12-02 US disclosed
US-7459580-B2 Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives SHIONOGI & CO., LTD. (JP) 2008-12-02 US disclosed
US-20080262264-A1 Process For the Preparation of Sulfomate-Carboxylate Derivatives SHIONOGI & CO., LTD. (JP) 2008-10-23 US disclosed
US-20080262264-A1 Process For the Preparation of Sulfomate-Carboxylate Derivatives SHIONOGI & CO., LTD. (JP) 2008-10-23 US disclosed
US-20080039662-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES SHIONOGI & CO., LTD. (JP) 2008-02-14 US disclosed
US-20080039662-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES SHIONOGI & CO., LTD. (JP) 2008-02-14 US disclosed
US-7314950-B2 Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative SHIONOGI & CO., LTD. (JP) 2008-01-01 US disclosed
US-7314950-B2 Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative SHIONOGI & CO., LTD. (JP) 2008-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090043094-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES ACMSD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AADAT MAPT 1721/4885ALDH1A1 532/4885CYP2C19 490/4885
US-20190308984-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 MAPT 4062/4885ALDH1A1 1361/4885CYP2C19 1541/4885
US-11345711-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 MAPT 4062/4885ALDH1A1 1361/4885CYP2C19 1541/4885
US-20080039662-A1 PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES AADAT, ACMSD, AAAS MAPT 1445/4885ALDH1A1 679/4885CYP2C19 551/4885
US-10703759-B2 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones WEE1, WEE2, CCNE1 MAPT 4062/4885ALDH1A1 1361/4885CYP2C19 1541/4885
US-20080262264-A1 Process For the Preparation of Sulfomate-Carboxylate Derivatives STS, ADH1C, ADH1A MAPT 4164/4885ALDH1A1 48/4885CYP2C19 149/4885
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH MAPT 4195/4885ALDH1A1 892/4885CYP2C19 4645/4885
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS TST, TPMT, MMP1 MAPT 4017/4885ALDH1A1 383/4885CYP2C19 2325/4885
US-20200385394-A1 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES WEE1, WEE2, CCNE1 MAPT 4062/4885ALDH1A1 1361/4885CYP2C19 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.